Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VYNE 
Vyne Therapeutics Inc (VYNE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VYNE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.03% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.83M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.76 | 52 Weeks Range 0.33 - 4.30 | Updated Date 08/15/2025 |
52 Weeks Range 0.33 - 4.30 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4552.97% |
Management Effectiveness
Return on Assets (TTM) -38.37% | Return on Equity (TTM) -66.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -44377955 | Price to Sales(TTM) 9.64 |
Enterprise Value -44377955 | Price to Sales(TTM) 9.64 | ||
Enterprise Value to Revenue 10.04 | Enterprise Value to EBITDA 1.84 | Shares Outstanding 16664900 | Shares Floating 13576221 |
Shares Outstanding 16664900 | Shares Floating 13576221 | ||
Percent Insiders 8.23 | Percent Institutions 50.47 |
Upturn AI SWOT
Vyne Therapeutics Inc
Company Overview
History and Background
Vyne Therapeutics Inc., formerly known as Menlo Therapeutics Inc., focuses on developing and commercializing therapeutics for dermatology. It was founded in 2003 (as Menlo) and has evolved through acquisitions and strategic shifts.
Core Business Areas
- Dermatology Therapeutics: Focuses on prescription dermatology products. Currently offering AMZEEQ(R) and Zilxi(R) for the treatment of acne. Developing innovative therapeutic alternatives addressing unmet needs in dermatology.
Leadership and Structure
The leadership team includes David Domzalski (CEO) and prominent board members. The organizational structure is typical of a publicly traded pharmaceutical company, with departments covering research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- AMZEEQ: AMZEEQ(R) (minocycline) is a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Market share data is not publicly available, but competitors include generic topical antibiotics and other acne treatments. Competing companies: Galderma, Bausch Health.
- Zilxi: Zilxi(R) (minocycline) is a topical foam used to treat inflammatory lesions of rosacea in adults. Market share data is not publicly available. Competing companies: Galderma, Foamix Pharmaceuticals (now part of Vyne).
Market Dynamics
Industry Overview
The dermatology market is characterized by growing demand for effective treatments for skin conditions like acne and rosacea. Trends include increasing awareness of skincare, new drug approvals, and innovative drug delivery systems.
Positioning
Vyne Therapeutics is positioned as a specialty dermatology company focused on delivering innovative therapies that address unmet needs in acne and rosacea. They aim to differentiate themselves through unique formulations and targeted marketing. They also position themselves on expanding the portfolio with differentiated assets.
Total Addressable Market (TAM)
The total addressable market for acne and rosacea treatments is estimated to be multi-billion dollars. Vyne Therapeutics' TAM is related to the acne and rosacea treatment markets, which is estimated to be in the billions. However, it's exact market size depends on pricing and market penetration of their products.
Upturn SWOT Analysis
Strengths
- FDA-approved products (AMZEEQ, Zilxi)
- Specialized focus on dermatology
- Strategic acquisitions (e.g., Foamix)
- Experienced management team
Weaknesses
- Limited product portfolio
- High dependence on a few key products
- Market acceptance risk
- Competition from established players
Opportunities
- Expanding product portfolio through R&D
- Geographic expansion
- Strategic partnerships and collaborations
- Capitalize on changing market trends in dermatology
Threats
- Generic competition
- Regulatory changes
- Economic downturn
- Changing consumer preferences
Competitors and Market Share
Key Competitors
- BHC
- GTH
- VRX
Competitive Landscape
Vyne's advantages include specialized focus and approved products. Disadvantages include smaller size and limited resources compared to competitors.
Major Acquisitions
Foamix Pharmaceuticals
- Year: 2020
- Acquisition Price (USD millions): 102.8
- Strategic Rationale: Acquisition of Foamix provided Vyne with Zilxi, strengthening its dermatology portfolio and commercial presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by fluctuations tied to product launches and acquisitions. Growth is dependent on product uptake in the market.
Future Projections: Future growth depends on success of new products and label expansions, as well as management execution. Projections require analyst reports.
Recent Initiatives: Recent strategic initiatives include focusing on commercializing core dermatology products, strengthening their financial position, and seeking business development opportunities.
Summary
Vyne Therapeutics is a smaller specialty dermatology company with FDA-approved products but faces competition from larger established players. Their success hinges on product adoption, strategic growth initiatives, and careful cost management. Vyne needs to carefully manage debt and expand product offerings. They also have to make sure that generic product competition does not reduce their marketshare.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vyne Therapeutics Inc
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2018-01-25 | CEO, President & Director Mr. David T. Domzalski | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://vynetherapeutics.com |
Full time employees 13 | Website https://vynetherapeutics.com | ||
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.